Clinical Trial Update: Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12 [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 trial evaluated the safety, tolerability, and immunogenicity of a Meningococcal B recombinant vaccine when given as a booster at 12, 18, o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease
• Meningococcal Meningitis

Drugs mentioned

• Bexsero (Meningococcal group B vaccine (4CMenB))

Snippet

Sponsor: Novartis Vaccines | Conditions: Meningococcal Disease, Meningococcal Meningitis | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2015-11-10